Search Site
Related Products
MLN8237 (Alisertib)
Aurora A Kinase inhibitor, Potent and selective

MLN8237 (Alisertib)

Catalog No. A4110
Size Price Stock Qty
10mM (in 1mL DMSO) $85.00 In stock
Evaluation Sample $28.00 In stock
5mg $75.00 In stock
10mg $130.00 In stock
50mg $410.00 In stock
200mg $1,070.00 In stock

Tel: +1-832-696-8203


Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

MLN8237 (Alisertib)

Related Biological Data

MLN8237 (Alisertib)

Related Biological Data

MLN8237 (Alisertib)

Related Biological Data

MLN8237 (Alisertib)

Biological Activity

Description Alisertib (MLN8237) is a selective inhibitor of Aurora A with IC50 of 1.2 nM. It has >200-fold higher selectivity for Aurora A than Aurora B.
Targets Aurora A          
IC50 1.2 nM          


Cell experiment: [1]

Cell lines

TIB-48 and CRL-2396 cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reacting condition

>100 nM, 48 hours


TIB-48 and CRL-2396 cells were treated with MLN8237 at 10 nM, 50 nM, 100 nM, 500 nM and 1.0 μ M for 48 h. MLN8237 induced apoptosis at concentrations >100 nM, suggesting that induction of apoptosis is dose-dependent. These results were confirmed by demonstrating an increased level of cleaved PARP in treated TIB-48 and CRL-2396 cells. PARP cleavage was observed even at the concentration of MLN8237 as low as 50 nM.

Animal experiment: [2]

Animal models

Female C.B-17 SCID mice injected with OVCAR-5-pWZL-Luc cells

Dosage form

Oral administration, 20 or 30 mg/kg, once daily (QD) or twice daily (BID)


The mice (n=16/group) were randomly divided into five treatment groups: 1) vehicle, 2) 20 mg/kg alisertib, 3) 30 mg/kg alisertib, 4) 5 mg/kg paclitaxel and 5) 20 mg/kg alisertib + 5 mg/kg paclitaxel. Tumor growth was monitored by weekly BLI and the log-transformed total flux data showed significantly decreased tumor growth rates in mice treated with alisertib (20 or 30 mg/kg) compared to vehicle-treated mice. Treatment with 20 mg/kg and 30 mg/kg alisertib resulted in 51% and 49% TGI, respectively.

her notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1] Qi W, Spier C, Liu X, et al. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leukemia research, 2013, 37(4): 434-439.

[2] Do T V, Xiao F, Bickel L E, et al. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene, 2013, 33(5): 539-549.

MLN8237 (Alisertib) Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


MLN8237 (Alisertib) Molarity Calculator



Chemical Properties

Cas No. 1028486-01-2 SDF Download SDF
Chemical Name 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
Canonical SMILES COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC
Formula C27H20ClFN4O4 M.Wt 518.92
Solubility Soluble in DMSO > 10 mM Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Research Update

1. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs. 2013 Feb;31(1):39-45. doi: 10.1007/s10637-012-9831-9. Epub 2012 Jun 6.
The combination of vorinsostat and MLN8237, a Aurora A kinase inhibitor, has the potential to exhibit enhanced antitumor activity against pediatric tumor cell lines through disrupting the spindle assembly and the mitotic checkpoint.
4. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]
MLN8237 exhibited modest activity with the maximum tolerated dose of 50 mg BID on the ECT 7-day schedule and the terminal half-life of 19 hours in a phase I study evaluating two regimes of MLN8237 in patients with relapsed or refractory heme-lymphatic malignancies, in which MLN8237 ECT of 50 mg BID for 7 days in 21-day cycles is recommended.


The orally bioavailable agent, MLN8237 (also known as alisertib), is a potent small-molecule inhibitor of Aurora A kinase (AAK) which is overexpressed in several types of tumor and  associated with oncogenesis and tumor progression. It was developed from its predecessor, MLN8054, in order to minimize the benzodiazepine-like effects seen with MLN8054. The inhibitory effect of MLN8237 is ATP-competitive, reversible and AAK-specific with an inhibition constant (Ki) of 0.43 nmol/L. MLN8237 is being investigated to treat advanced malignancies, due to its both in vitro and in vivo activities against a broad range of tumor types.


E. Claire Dees, Roger B. Cohen, Margaret von Mehren, Thomas E. Stinchcombe, Hua Liu, Karthik Venkatakrishnan, Mark Manfredi, Howard Fingert, Howard A. Burris III, and Jeffrey R. Infante. Phase I study of aurora A kniase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 2012; 18:4775-4784.